These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 38420497)

  • 1. Real-world effectiveness of erenumab in Japanese patients with migraine.
    Suzuki K; Suzuki S; Shiina T; Haruyama Y; Kobayashi S; Shioda M; Hirata K
    Heliyon; 2024 Feb; 10(4):e26568. PubMed ID: 38420497
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of switching to erenumab in non-responders to a CGRP ligand antibody treatment in migraine: A real-world cohort study.
    Overeem LH; Lange KS; Fitzek MP; Siebert A; Steinicke M; Triller P; Hong JB; Reuter U; Raffaelli B
    Front Neurol; 2023; 14():1154420. PubMed ID: 37034092
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of three calcitonin gene-related peptide monoclonal antibodies for migraine: A 12-month, single-center, observational real-world study in Japan.
    Suzuki K; Suzuki S; Shiina T; Tatsumoto M; Fujita H; Haruyama Y; Hirata K
    Cephalalgia; 2023 May; 43(5):3331024231177649. PubMed ID: 37231663
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Does MIDAS reduction at 3 months predict the outcome of erenumab treatment? A real-world, open-label trial.
    De Icco R; Vaghi G; Allena M; Ghiotto N; Guaschino E; Martinelli D; Ahmad L; Corrado M; Bighiani F; Tanganelli F; Bottiroli S; Cammarota F; Sances G; Tassorelli C
    J Headache Pain; 2022 Sep; 23(1):123. PubMed ID: 36115947
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term (48 weeks) effectiveness, safety, and tolerability of erenumab in the prevention of high-frequency episodic and chronic migraine in a real world: Results of the EARLY 2 study.
    Barbanti P; Aurilia C; Cevoli S; Egeo G; Fofi L; Messina R; Salerno A; Torelli P; Albanese M; Carnevale A; Bono F; D'Amico D; Filippi M; Altamura C; Vernieri F;
    Headache; 2021 Oct; 61(9):1351-1363. PubMed ID: 34309862
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of antibody switch in non-responders to a CGRP receptor antibody treatment in migraine: A multi-center retrospective cohort study.
    Overeem LH; Peikert A; Hofacker MD; Kamm K; Ruscheweyh R; Gendolla A; Raffaelli B; Reuter U; Neeb L
    Cephalalgia; 2022 Apr; 42(4-5):291-301. PubMed ID: 34644203
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Two-year effectiveness of erenumab in resistant chronic migraine: a prospective real-world analysis.
    Andreou AP; Fuccaro M; Hill B; Murphy M; Caponnetto V; Kilner R; Lambru G
    J Headache Pain; 2022 Nov; 23(1):139. PubMed ID: 36333710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of a reimbursement policy change on treatment with erenumab in migraine - a real-world experience from Germany.
    Hong JB; Lange KS; Fitzek M; Overeem LH; Triller P; Siebert A; Reuter U; Raffaelli B
    J Headache Pain; 2023 Oct; 24(1):144. PubMed ID: 37899428
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-World Patient Experience With Erenumab for the Preventive Treatment of Migraine.
    Robblee J; Devick KL; Mendez N; Potter J; Slonaker J; Starling AJ
    Headache; 2020 Oct; 60(9):2014-2025. PubMed ID: 32920850
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Erenumab in the prevention of high-frequency episodic and chronic migraine: Erenumab in Real Life in Italy (EARLY), the first Italian multicenter, prospective real-life study.
    Barbanti P; Aurilia C; Egeo G; Fofi L; Cevoli S; Colombo B; Filippi M; Frediani F; Bono F; Grazzi L; Salerno A; Mercuri B; Carnevale A; Altamura C; Vernieri F
    Headache; 2021 Feb; 61(2):363-372. PubMed ID: 33337544
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Erenumab for episodic migraine prophylaxis.
    Overeem LH; Neeb L; Reuter U
    Expert Rev Neurother; 2019 Aug; 19(8):751-757. PubMed ID: 30614741
    [No Abstract]   [Full Text] [Related]  

  • 12. Real-world experience of erenumab in patients with chronic or episodic migraine in the UAE.
    Alsaadi T; Noori S; Varakian R; Youssef S; Almadani A
    BMC Neurol; 2022 Jun; 22(1):221. PubMed ID: 35710354
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-World Evidence for the Safety and Efficacy of CGRP Monoclonal Antibody Therapy Added to OnabotulinumtoxinA Treatment for Migraine Prevention in Adult Patients With Chronic Migraine.
    Mechtler L; Saikali N; McVige J; Hughes O; Traut A; Adams AM
    Front Neurol; 2021; 12():788159. PubMed ID: 35069416
    [No Abstract]   [Full Text] [Related]  

  • 14. Ultra-late response (> 24 weeks) to anti-CGRP monoclonal antibodies in migraine: a multicenter, prospective, observational study.
    Barbanti P; Aurilia C; Egeo G; Proietti S; D'Onofrio F; Torelli P; Aguggia M; Bertuzzo D; Finocchi C; Trimboli M; Cevoli S; Fiorentini G; Orlando B; Zucco M; Di Clemente L; Cetta I; Colombo B; di Poggio MLB; Favoni V; Grazzi L; Salerno A; Carnevale A; Robotti M; Frediani F; Altamura C; Filippi M; Vernieri F; Bonassi S;
    J Neurol; 2024 May; 271(5):2434-2443. PubMed ID: 38231271
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A head-to-head observational cohort study on the efficacy and safety of monoclonal antibodies against calcitonin gene-related peptide for chronic and episodic migraine.
    Saccà F; Braca S; Sansone M; Miele A; Stornaiuolo A; De Simone R; Russo CV
    Headache; 2023 Jun; 63(6):788-794. PubMed ID: 37254581
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-Term Effectiveness of Three Anti-CGRP Monoclonal Antibodies in Resistant Chronic Migraine Patients Based on the MIDAS score.
    Iannone LF; Fattori D; Benemei S; Chiarugi A; Geppetti P; De Cesaris F
    CNS Drugs; 2022 Feb; 36(2):191-202. PubMed ID: 35146696
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Erenumab in highly therapy-refractory migraine patients: First German real-world evidence.
    Scheffler A; Messel O; Wurthmann S; Nsaka M; Kleinschnitz C; Glas M; Naegel S; Holle D
    J Headache Pain; 2020 Jul; 21(1):84. PubMed ID: 32620151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Post hoc analysis of clinical trial data and pharmacokinetic data to assess wearing-off of erenumab within monthly treatment cycle.
    Dodick DW; Blumenfeld AM; Halker Singh RB; Williams R; Zhang F; Chen PW; Hsu CP; Peng C; Snellman J; Chehrenama M; Ailani J
    Headache; 2023 Feb; 63(2):233-242. PubMed ID: 36226464
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discontinuing monoclonal antibodies targeting CGRP pathway after one-year treatment: an observational longitudinal cohort study.
    Vernieri F; Brunelli N; Messina R; Costa CM; Colombo B; Torelli P; Quintana S; Cevoli S; Favoni V; d'Onofrio F; Egeo G; Rao R; Filippi M; Barbanti P; Altamura C
    J Headache Pain; 2021 Dec; 22(1):154. PubMed ID: 34922444
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-world long-term efficacy and safety of erenumab in adults with chronic migraine: a 52-week, single-center, prospective, observational study.
    Cullum CK; Do TP; Ashina M; Bendtsen L; Hugger SS; Iljazi A; Gusatovic J; Snellman J; Lopez-Lopez C; Ashina H; Amin FM
    J Headache Pain; 2022 Jun; 23(1):61. PubMed ID: 35655137
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.